Kyverna Therapeutics’ IND application for MS therapy receives FDA clearance

Worldwide, over 2.8 million individuals suffer from MS, which causes symptoms ranging from blurred vision and slurred speech to severe mobility issues. Credit: WikiImag.es from Pixabay.